BIO-TECHNE CORP (TECH) 81.19 +0.87 (+1.08%)
81.19 +0.87 (+1.08%)
US09073M1045 - Common Stock - After market: 81.19 0 (0%)
Fundamental Rating
Taking everything into account, TECH scores 6 out of 10 in our fundamental rating. TECH was compared to 66 industry peers in the Life Sciences Tools & Services industry. TECH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. TECH shows excellent growth, but is valued quite expensive already. This could make TECH a good candidate for growth investing.
Profitability
Profitability Rating
TECH has a Return On Assets of 12.42%. This is better than the industry average of 8.42%.
TECH's Profit Margin of 26.12% is amongst the best returns of the industry. TECH outperforms 86% of its industry peers. The industry average Profit Margin is 16.49%.
The Piotroski-F score of TECH is 8.00. This is a very strong score and indicates great health and profitability for TECH.
TECH's Return On Equity of 16.67% is in line with the rest of the industry. The industry average Return On Equity is 16.61%.
VS Industry
ROA (12.42%) VS Industry: 69% outperformed.
0.30
57.39
ROE (16.67%) VS Industry: 54% outperformed.
1.18
180.91
Profit Margin (26.12%) VS Industry: 86% outperformed.
0.20
383.95
Valuation
Valuation Rating
With a price book ratio of 7.28, TECH is valued correctly.
The Price/Earnings Ratio is 41.42, which means the current valuation is very expensive for TECH.
With a Price/Earning Ratio of 41.42, TECH is valued a higher than the industry average, which is at 28.09. 84% of the companies listed in the same industry are cheaper than TECH!
The Forward Price/Earnings Ratio of 32.25 indicates a quite expensive current valuation of TECH.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates TECH does not grow enough to justify the current Price/Earnings ratio.
Compared to an average industry price book ratio of 2.48, TECH is valued more expensive than its industry peers. 87% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of TECH to the average industry ratio of 20.48, TECH is valued more expensive than its industry peers.
VS Industry
Price/Earnings (41.42) VS Industry: 16% outperformed.
109.42
7.26
Price/Book (7.28) VS Industry: 13% outperformed.
51.37
0.32
Enterprise Value/ EBITDA (32.06) VS Industry: 21% outperformed.
639.94
2.24
Growth
Growth Rating
TECH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.41%, which is quite good.
TECH shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 16.32% yearly.
Based on estimates for the next 5 years, TECH will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.79% on average per year.
The Revenue has grown by 13.50% in the past year. This is quite good.
The Revenue has been growing by 14.45% on average over the past 5 years. This is quite good.
Based on estimates for the next 5 years, TECH will show a quite strong growth in Revenue. The Revenue will grow by 14.36% on average per year.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 16.32% | 20.63% | 10.41% | 8.21% | 12.9% | 12.79% | N/A |
| Revenue | 14.45% | 15.69% | 13.5% | 8.51% | 10.89% | 10.79% | 14.36% |
Health
Health Rating
TECH has a Current Ratio of 4.01. This indicates that TECH is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.92 indicates that TECH has no problem at all paying its short term obligations.
TECH has an Altman-Z score of 14.55. This indicates that TECH is financially healthy and little risk of bankruptcy at the moment.
TECH has one of the better Altman-Z scores in its industry. It is much better than the industry average of 2.69. TECH has a better score than 93% of its industry peers.
The Piotroski-F score of TECH is 8.00. This is a very strong score and indicates great health and profitability for TECH.
The Current Ratio is in line with the industry averages, which is at 4.77.
The Quick Ratio is in line with the industry averages, which is at 4.30.
The Debt to Equity ratio of TECH is in line with the industry averages.
VS Industry
Debt/Equity (0.15) VS Industry: 42% outperformed.
3.88
0.00
Quick Ratio (2.92) VS Industry: 43% outperformed.
0.04
40.60
Current Ratio (4.01) VS Industry: 47% outperformed.
0.04
40.60
Altman-Z (14.55) VS Industry: 93% outperformed.
-152.47
23.50
Dividend
Dividend Rating
Compared to an average industry Dividend Yield of 0.36, TECH pays a bit more dividend than its industry peers.
17.21% of the earnings are spent on dividend by TECH. This is a low number and sustainable payout ratio.
TECH has been paying a dividend for at least 10 years, so it has a reliable track record.
With a yearly dividend of 0.39%, TECH is not a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.41, TECH's dividend is way lower than the S&P500 average.
VS Industry
Dividend Yield (0.39%) VS Industry: 71% outperformed.
0.20
0.72
BIO-TECHNE CORP81.19
NASDAQ:TECH (1/27/2023, 7:00:02 PM)+0.87 (+1.08%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Life Sciences Tools & Services | ||
| Earnings (Last) | 11-01 2022-11-01/bmo | Earnings (Next) | 01-30 2023-01-30 |
| Inst Owners | 25.66% | Inst Owner Change | 8.92% |
| Ins Owners | 0.76% | Ins Owner Change | 13.43% |
| Market Cap | 12.74B | Analysts | 83 |
| Price Target | 106.99 (31.78%) | ||
| Dividend Yield | 0.39% | Dividend Growth | N/A |
| DP | 17.21% | Ex-Date | N/A |
| EPS beat(2) | N/A | Avg EPS beat(2) | -3.96% |
| Min EPS beat(2) | -4.66% | Max EPS beat(2) | -3.25% |
| EPS beat(4) | 2 | Avg EPS beat(4) | -0.01% |
| Min EPS beat(4) | -4.66% | Max EPS beat(4) | 5.04% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | -3.87% |
| Min Revenue beat(2) | -6.16% | Max Revenue beat(2) | -1.58% |
| Revenue beat(4) | 1 | Avg Revenue beat(4) | -1.69% |
| Min Revenue beat(4) | -6.16% | Max Revenue beat(4) | 1.94% |
| PT rev (1m) | 0% | EPS NQ rev (1m) | N/A |
| EPS NY rev (1m) | 0% | Revenue NQ rev (1m) | N/A |
| Revenue NY rev (1m) | 0% | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.42 | ||
| Fwd PE | 32.25 | ||
| P/S | 11.4 | ||
| P/FCF | 44.79 | ||
| P/OCF | 38.28 | ||
| P/B | 7.28 | ||
| P/tB | 42.45 | ||
| EV/EBITDA | 32.06 |
| EPS(TTM) | 1.96 | EY | 2.41% |
| EPS(NY) | 2.52 | Fwd EY | 3.1% |
| FCF(TTM) | 1.81 | FCFY | 2.23% |
| OCF(TTM) | 2.12 | OCFY | 2.61% |
| SpS | 7.12 | BVpS | 11.16 |
| TBVpS | 1.91 | PEG (NY) | 5.05 |
| PEG (5Y) | 2.54 | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.42% | ||
| ROE | 16.67% | ||
| ROIC | 12.11% | ||
| ROICexc | 13.33% | ||
| ROICexgc | 47.93% | ||
| OM | 26.42% | ||
| PM | 26.12% | ||
| GM | 68.46% |
| ROICexgc(3y) | 46.3% | ROICexcg growth 3Y | 5.54% |
| ROICexcg growth 5Y | -1.65% | ROICexc(3y) | 11.53% |
| ROICexc growth 3Y | 20.01% | ROICexc growth 5Y | 6.6% |
| OM growth 3Y | 8.93% | OM growth 5Y | 0.74% |
| PM growth 3Y | 22.3% | PM growth 5Y | 12.72% |
| GM growth 3Y | 1.05% | GM growth 5Y | 0.57% |
| F-Score | 8 | Asset Turnover | 0.48 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | 0.93 | ||
| Debt/EBITDA | 0.66 | ||
| Cap/Depr | 47% | ||
| Profit Quality | 97.48% | ||
| Current Ratio | 4.01 | ||
| Quick Ratio | 2.92 | ||
| Altman-Z | 14.55 |
| F-Score | 8 | WACC | 9.65% |
| ROIC/WACC | 4.97 | Cap/Depr(3y) | 52.48% |
| Cap/Depr(5y) | 44.46% | Profit Quality(3y) | 129.83% |
| Profit Quality(5y) | 134.13% | ||
| EPS 1Y | 10.41% | EPS 3Y | 20.63% |
| EPS 5Y | 16.32% | EPS growth Q2Q | -2.73% |
| EPS Next Y | 8.21% | EPS Next 2Y | 12.9% |
| EPS Next 3Y | 12.79% | EPS Next 5Y | N/A |
| Revenue growth 1Y | 13.5% | Revenue growth 3Y | 15.69% |
| Revenue growth 5Y | 14.45% | Revenue growth Q2Q | 4.63% |
| Revenue Next Year | 8.51% | Revenue Next 2Y | 10.89% |
| Revenue Next 3Y | 10.79% | Revenue Next 5Y | 14.36% |
| EBIT growth 1Y | 14.52% | EBIT growth 3Y | 26.03% |
| EBIT growth 5Y | 15.29% | EBIT Next Year | 12.87% |
| EBIT Next 3Y | 14.85% | EBIT Next 5Y | N/A |
| FCF growth 1Y | 59.31% | FCF growth 3Y | 21.53% |
| FCF growth 5Y | 16.89% | OCF growth 1Y | 44.31% |
| OCF growth 3Y | 21.44% | OCF growth 5Y | 17.75% |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA